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methotrexate both in severe and highly active RA. METHODS:
A lifetime deterministic Markov model was developed compar-
ing two treatment sequences within two hypothetical cohorts of
patients. Five to six treatment sequences were considered in each
arm. Patients switched to the next sequence in case of lack of
effectiveness or in case of severe adverse events. Patients’ health
status was deﬁned by the Health Assessment Questionnaire
(HAQ), scale which demonstrated strong links with mortality
and quality of life. Scores were updated at every six-month model
cycles. Treatment failure occurred if the score did not improve by
0.35 point over the cycle. HAQ scores were converted into utility
coefﬁcients. Effectiveness data (HAQ progression, serious
adverse events and mortality) were derived from TEMPO trial
and literature. Only direct medical costs were considered.
Resource use was estimated through published data and expert
opinion. Costs were derived from French ofﬁcial sources. Sensi-
tivity analyses were performed on main model parameters.
RESULTS: The results showed that QALYs (Quality-Adjusted
Life-Years) were increased respectively in severe and highly active
RA by 0.98 (9.10vs8.12) and 0.73 (10.52vs9.78) in patients
treated with etanercept as 1st line compared with etanercept as
2nd line. The lifetime costs per patient were respectively in severe
and highly active RA €214,327 and €233,262 with etanercept as
1st line and €190,236 and €211,148 with etanercept as 2nd line
agent. Incremental cost-effectiveness ratios (ICER) were respec-
tively in severe and highly active RA: €24,655 and €30,199 per
QALY. Ratios ranged from €10,784 to €83,174 per QALY in
one-way sensitivity analyses. CONCLUSIONS: Treatment
sequence including etanercept as 1st line may be cost-effective in
the management of severe and highly active RA in France with
ICER fallen within acceptable range.
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OBJECTIVES: Poor compliance and failure to persist with drug
therapy are of potential economic signiﬁcance. The objective of
this study is to assess the impact of medication non-compliance
and non-persistence on economic evaluations in osteoporosis.
METHODS: A Markov microsimulation model with a lifetime
horizon and a societal perspective was used to analyse the impact
of non-adherence to biphosphonate therapy on costs (drug,
disease and total), on outcomes (Quality-Adjusted Life Years and
number of fractures saved) and on the cost-utility of biphospho-
nate therapy versus no treatment. Analyses were performed for
caucasian women aged 70 years with a diagnosis of osteoporosis
(t-score  -2.5). The relationship between compliance and frac-
ture efﬁcacy were taken from published sources and drug cost
was proportionate to compliance level. To model persistence to
therapy, we assumed that women can stop therapy after 3
months, 6 months, 1 year, 2 years or 3 years. RESULTS: Full
adherence to therapy resulted in a QALY gain of 0.0397, a 7.6%
reduction in the number of fractures and a higher cost of €383
compared to no treatment. Lower compliance was associated
with a decrease in QALY gain, a reduction in the number of
fractures saved and a higher disease cost compensated by a lower
drug cost. The cost per QALY gained for biphosphonate therapy
versus no treatment increased progressively with decreasing com-
pliance and was €9,653 €29,570 and €46,389 at 100%, 50% and
20% of compliance respectively. Realistic persistence assumption
(with full compliance) resulted in a lower QALY gain (only
0.0165) and a higher cost per QALY gained (€12,479). CON-
CLUSIONS: This study indicated that non-compliance and non-
persistence to osteoporotic therapy result not only in worsening
health outcomes, but also in a signiﬁcant change in cost-
effectiveness. Therefore, the effects of non-compliance and non-
persistence should be an integral part of economic evaluations in
osteoporosis.
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OBJECTIVES: New biologic therapies with distinct mechanisms
of action offer alternatives to rheumatologists and hope to
patients with moderate to severely active rheumatoid arthritis
(RA) and an inadequate response to anti-TNF therapy. The
objective of this study was to assess the cost-effectiveness of
abatacept and rituximab in biologic treatment sequences in
patients with RA and an inadequate response to one anti-TNF
agent. METHODS: An advanced simulation model was devel-
oped to assess the cost-effectiveness of two biologic strategies in
etanercept inadequate-responders: Strategy A—abatacept fol-
lowed by adalimumab (in case of an inadequate response to
abatacept); Strategy B—rituximab followed by adalimumab (in
case of an inadequate response to rituximab). Two clinically
relevant effectiveness endpoints were used: low disease activity
state (LDAS) (DAS28 3.2) and remission (DAS28 <2.6). Effec-
tiveness estimates for abatacept and rituximab were derived
from published pivotal trials and long-term extension studies,
assuming similar patient populations. Overall effectiveness was
expressed in theoretical expected number of days (TEND) under
remission or LDAS for each sequence after 2 years. French RA
direct medical costs were derived from a costing model based on
DAS28 categories. Using 4 ¥ 6-month cycles, drug costs were
estimated based on recommended dosing. Assuming a sustained
response over 6-month cycles, the rituximab re-treatment inter-
val was set at 6 months. Monte-Carlo simulations generated
mean values and standard deviations of costs, effectiveness and
mean cost-effectiveness over 2 years. Signiﬁcance tests were
performed to conﬁrm differences. RESULTS: Using the LDAS
endpoint, Strategy A (abatacept as second biologic agent) was
signiﬁcantly more efﬁcacious over 2 years versus (vs) Strategy B
(rituximab as second biologic agent), with 134 vs 107 TEND
under LDAS (p < 0.01). Mean cost-effectiveness ratios showed
signiﬁcantly lower overall medical costs per TEND under LDAS
with Strategy A vs Strategy B (€212 vs €234; p < 0.01). Using the
remission endpoint, Strategy A (abatacept as second biologic
agent) was signiﬁcantly more efﬁcacious over 2 years vs Strategy
B (rituximab as second biologic agent), with 61 vs 37 TEND
under remission (p < 0.01). Mean cost-effectiveness ratios
showed signiﬁcantly lower overall medical costs per TEND
under remission with Strategy A vs Strategy B (€446 vs €642;
p < 0.01). CONCLUSIONS: This innovative and robust model is
the ﬁrst to use LDAS and remission to compare biologic strate-
gies in France, aligned with RA treatment goals. The results
suggest that when used as the second biologic agent after an
inadequate response to one anti-TNF agent, abatacept appears
signiﬁcantly more efﬁcacious and cost-effective than ritux-
imab.This innovative and robust model is the ﬁrst to use LDAS
A542 Abstracts
and remission to compare biologic strategies in France, aligned
with RA treatment goals. The results suggest that when used as
the second biologic agent after an inadequate response to one
anti-TNF agent, abatacept appears signiﬁcantly more efﬁcacious
and cost-effective than rituximab.
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OBJECTIVES: To evaluate cost-effectiveness of TNF-a inhibitors
(adalimumab, etanercept and inﬂiximab) in the treatment of
ankylosing spondylitis (AS) in polish settings. METHODS:
Markov model was adapted for two health states: response and
non-response according to ASAS20 criteria and cycle time was 3
months. Analysis was performed from the perspective of public
payer (National Heath Fund) in the 1 year and life-time horizons.
Costs analyzed: acquisition costs of drugs, drug administration
and treatment monitoring costs, adverse events treatment costs,
AS hospitalization costs, tuberculosis monitoring and treatment
costs. Health outcomes included quality-adjusted life-year
(QALY). Data from systematic review of published randomized
clinical trials were used to evaluate transition probabilities
during anti-TNF-a or comparator (standard AS therapy—
NSAID and/or DMARD’s) treatment. Utility values were calcu-
lated from BASFI, BASDAI, sex and age data based on published
algorithm. Costs and effects were discounted 5% annually.
Univariate and probabilistic sensitivity analyses were performed.
Values are presented in PLN (exchange rate: 1 Euro = 3.40 PLN).
RESULTS: In the base-case analysis QALY gains of 0.063 and
0.302 were estimated for patients treated with adalimumab,
etanercept or inﬂiximab in 1-year and life-time horizon, respec-
tively. ICER/QALY in one year horizon was 597,455, 597,169
and 796,076 PLN/QALY for adalimumab, etanercept and inﬂix-
imab, respectively. In life-time horizon ICER/QALY was
405,430, 405,235 and 471,707 PLN/QALY for adalimumab,
etanercept and inﬂiximab, respectively. CONCLUSIONS: Anti-
TNF-alfa treatment is currently unattractive for all AS patients in
polish health care settings, thus further analysis are needed to
identify subgroups of patients who beneﬁt most to ensure effec-
tive resources allocation.
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OBJECTIVES: To evaluate the cost-effectiveness of etanercept
combination therapy with methotrexate (MTX) versus rituximab
with MTX for rheumatoid arthritis (RA) from a payer’s perspec-
tive in Colombia. METHODS: A literature-based decision ana-
lytic model was constructed with a one year time horizon to
compare the cost-effectiveness of etanercept 25 mg twice-
weekly + MTX versus rituximab 2 ¥ 1000mg infusion + MTX in
RA patients with an inadequate response to disease-modifying
anti-rheumatic drugs. The primary measure of clinical effective-
ness was based on remission (Disease Activity Score 28 joint
count < 2.6). The model incorporated major and minor infec-
tious events, discontinuation due to lack of efﬁcacy or adverse
event, and rituximab re-treatment within the one year time-
horizon. Drug costs were based on average wholesale price. Cost
of managing adverse events and infusion costs were compiled
based on queries to Colombian rheumatologists. Sensitivity
analysis was conducted in the 30% price range and efﬁcacy
parameters for etanercept and rituximab. RESULTS: One year
total treatment costs for rituximab were COL$37,442,828 and
COL$39,825,456 for etanercept. The percent of patients achiev-
ing remission was 3% for rituximab and 27% for etanercept at
the end of 1 year. The incremental cost-effectiveness ratio (ICER)
was COL$9931,754 per additional patient achieving remission.
The number needed to treat was 29 for rituximab and 5 for
etanercept. Given a hypothetical budget of COL$1,000,000,000,
the number of patients achieving remission was 7 for etanercept
and 1 for rituximab. Sensitivity analysis showed that etanercept
continued to have more patients achieving remission than ritux-
imab even if the drug cost and efﬁcacy was varied by 30%
given a deﬁned budget. CONCLUSIONS: The results suggest
that etanercept appears to be cost-effective compared to ritux-
imab. Additionally, more patients can be successfully treated to
remission with etanercept than rituximab given a deﬁned budget.
These ﬁndings were robust for plausible ranges of effectiveness
and drug acquisition costs.
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OBJECTIVES: The clinical beneﬁt of initial combination therapy
with inﬂiximab in patients with rheumatoird arthritis was estab-
lished in BeSt, a randomized clinical trial assessing the impact of
four treatment strategies in patients recently (less than 2 years)
diagnosed with RA. Treatment options were sequential mono-
therapy with DMARDs (group 1), step-up combination therapy
(group 2), initial combination therapy with tapered high-dose
prednisone (group 3), and initial combination therapy with
inﬂiximab (group 4). The cost-effectiveness of initial combina-
tion therapy with inﬂiximab vs. sequential DMARD mono-
therapy was evaluated. METHODS: Data on clinical outcomes
(Health Assessment Questionnaire [HAQ]) were extracted from
the two-year publication of BeSt and extrapolated to ﬁve years.
Medical resource use and drug costs (2006 £) were obtained
from the British National Formulary and two systematic NICE
reviews of TNF-a inhibitors in RA. Model outcomes, from a UK
payer perspective, included cost per one-point improvement in
HAQ and cost per quality-adjusted life-year (QALY); cost and
beneﬁt were discounted at 3.5%. HAQ scores were translated
into QALYs using an established algorithm. Probabilistic sensi-
tivity analyses were conducted to determine the impact of drug
cost, HAQ improvement, and translation between HAQ and
QALY. RESULTS: Initial combination therapy with prednisone
or inﬂiximab led to earlier HAQ improvement vs. sequential
monotherapy and step-up combination therapy. Cumulative
costs in group 1 increased from £1,155 to £15,875; costs in
group 4 rose from £8,131 to £22,155. QALYs improved more in
group 4 (0.70 to 3.30) than in group 1 (0.62 to 2.91). Cost per
QALY declined from £92,764 (year 1) to £15,965 (year 5) for
initial combination therapy with inﬂiximab vs. sequential mono-
therapy. Results were not sensitive to changes in drug cost, HAQ,
or the conversion algorithm. CONCLUSIONS: Higher costs
associated with the earlier use of inﬂiximab are offset by this
regimen’s clinical beneﬁt over time.
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